Global S&T Development Trend Analysis Platform of Resources and Environment
Industrial strategy delivers new vaccines manufacturing centre to lead the fight against deadly disease | |
admin | |
2018-12-01 | |
发布年 | 2018 |
语种 | 英语 |
国家 | 英国 |
领域 | 气候变化 |
正文(英文) | Press release Industrial strategy delivers new vaccines manufacturing centre to lead the fight against deadly diseaseEbola and Lassa fever are among the deadly diseases to be tackled in a pioneering new UK vaccine centre. ![]()
Ebola and Lassa fever are among the deadly diseases to be tackled in a pioneering new UK vaccine centre, Business Secretary Greg Clark announced today (Saturday 1 December). Based in Oxford, the Vaccines Manufacturing Innovation Centre will help to tackle disease worldwide as well as further boosting the growth of the UK’s £70 billion life sciences industry. Business Secretary Greg Clark said:
The availability of safe, effective and economical vaccines is an important pillar of world health. Alongside more familiar diseases, populations globally are threatened by new outbreaks of diseases such as Ebola and Lassa fever. In the Democratic Republic of the Congo, for example, an outbreak of Ebola beginning last August has resulted in 357 confirmed cases and 186 deaths, while this year a Lassa fever outbreak in Nigeria has resulted in 553 confirmed cases and 143 deaths. There are presently no licensed vaccines available for these diseases. The UK’s world-leading research and innovation expertise is ideally placed to create new, cost-effective ways of developing and manufacturing vaccines for global distribution, as well as ensuring the UK’s own preparedness in the event of a pandemic. The centre is expected to open in 2022, with the first products from the centre expected later that year. Public Health Minister Steve Brine said:
UK Research and Innovation Chief Executive Professor Sir Mark Walport said:
Led by the Jenner Institute, a partnership between the University of Oxford and the Pirbright Institute, the new centre has been awarded funding by UK Research and Innovation of £66 million through the UK government’s Industrial Strategy Challenge Fund (ISCF) Medicines Manufacturing challenge. Jenner Institute Director, Professor Adrian Hill, said:
The Industrial Strategy Challenge Fund aims to bring together the UK’s world-leading research with business to meet the major industrial and societal challenges of our time, backed by the biggest increase in public research and development investment in UK history. The investment marks a significant step in delivering on a major commitment in the Life Sciences Sector Deal, a partnership between government and industry ensuring the UK remains at the forefront of developing innovative new treatments and medical technologies to improve patients’ lives. Additional funding of £10 million will come from commercial and other partners, including Janssen Vaccines & Prevention B.V. and Merck Sharp and Dohme. The centre will be further supported by expertise and training from GE Healthcare. The core research teams will be drawn from academia and industry and will include significant new contributions from the London School of Hygiene & Tropical Medicine and Imperial College London as well as the University of Oxford. The programme will also benefit from access to technologies and intellectual property created by the partners.
Published 1 December 2018
|
URL | 查看原文 |
来源平台 | GOV.UK - Department for Business, Energy & Industrial Strategy |
文献类型 | 新闻 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/105471 |
专题 | 气候变化 |
推荐引用方式 GB/T 7714 | admin. Industrial strategy delivers new vaccines manufacturing centre to lead the fight against deadly disease. 2018. |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
查看访问统计 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[admin]的文章 |
百度学术 |
百度学术中相似的文章 |
[admin]的文章 |
必应学术 |
必应学术中相似的文章 |
[admin]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论